Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.
Saved in:
| Title: | Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies. |
|---|---|
| Authors: | Ferrari M; Research Division, Autolus Therapeutics, London, UK., Parekh F; Research Division, Autolus Therapeutics, London, UK., Maciocia P; Research Department of Haematology, University College London, London, UK., Horna P; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Thomas S; Research Division, Autolus Therapeutics, London, UK., Sewell AK; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.; Systems Immunity Research Institute, Cardiff University, Cardiff, UK., Pule M; Research Division, Autolus Therapeutics, London, UK. m.pule@ucl.ac.uk.; Research Department of Haematology, University College London, London, UK. m.pule@ucl.ac.uk. |
| Source: | Nature communications [Nat Commun] 2025 Jan 29; Vol. 16 (1), pp. 1103. Date of Electronic Publication: 2025 Jan 29. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-56396-7 |
